Compass Pathways appoints Justin Gover to board; Dr. Linda McGoldrick to retire Oct 31

COMPASS Pathways plc

Justin Gover appointed as Class III director effective July 29, 2025; joins audit/risk and scientific committees.
Gover receives initial option for 52,000 ordinary shares vesting over 3 years; annual retainer of $40,000 plus committee fees.
Linda McGoldrick to retire from board effective October 31, 2025; no disagreement with company.
Gover was founding CEO of GW Pharmaceuticals (sold to Jazz for $7B) and led Epidiolex development/commercialization.
Currently also serves on Xenon Pharmaceuticals (XENE) board; brings 25+ years biopharma experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.